Wealthfront Advisers’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.25M | Sell |
76,210
-22,894
| -23% | -$1.24M | 0.01% | 529 |
|
|
2026
Q1 | $6.22M | Sell |
99,104
-27,180
| -22% | -$2.17M | 0.01% | 373 |
|
|
2025
Q4 | $12M | Sell |
126,284
-20,222
| -14% | -$1.98M | 0.03% | 217 |
|
|
2025
Q3 | $14.3M | Sell |
146,506
-1,589
| -1% | -$165K | 0.03% | 170 |
|
|
2025
Q2 | $15.9M | Buy |
148,095
+6,902
| +5% | +$698K | 0.04% | 145 |
|
|
2025
Q1 | $14.2M | Buy |
141,193
+27,075
| +24% | +$2.73M | 0.04% | 145 |
|
|
2024
Q4 | $10.2M | Buy |
114,118
+7,338
| +7% | +$646K | 0.03% | 183 |
|
|
2024
Q3 | $8.95M | Buy |
106,780
+3,032
| +3% | +$239K | 0.03% | 183 |
|
|
2024
Q2 | $7.99M | Buy |
103,748
+4,425
| +4% | +$324K | 0.03% | 180 |
|
|
2024
Q1 | $6.8M | Buy |
99,323
+2,520
| +3% | +$162K | 0.02% | 208 |
|
|
2023
Q4 | $5.6M | Buy |
96,803
+7,917
| +9% | +$423K | 0.02% | 218 |
|
|
2023
Q3 | $4.69M | Buy |
88,886
+5,887
| +7% | +$309K | 0.02% | 228 |
|
|
2023
Q2 | $4.49M | Buy |
82,999
+17,659
| +27% | +$922K | 0.02% | 238 |
|
|
2023
Q1 | $3.27M | Buy |
65,340
+7,920
| +14% | +$373K | 0.01% | 286 |
|
|
2022
Q4 | $2.66M | Sell |
57,420
-4,371
| -7% | -$189K | 0.01% | 332 |
|
|
2022
Q3 | $2.39M | Buy |
61,791
+24,002
| +64% | +$963K | 0.01% | 327 |
|
|
2022
Q2 | $1.41M | Sell |
37,789
-929
| -2% | -$37.8K | 0.01% | 437 |
|
|
2022
Q1 | $1.71M | Buy |
38,718
+3,307
| +9% | +$143K | 0.01% | 431 |
|
|
2021
Q4 | $1.5M | Sell |
35,411
-144
| -0.4% | -$6.05K | 0.01% | 441 |
|
|
2021
Q3 | $1.54M | Buy |
35,555
+4,476
| +14% | +$198K | 0.01% | 398 |
|
|
2021
Q2 | $1.33M | Buy |
31,079
+3,660
| +13% | +$154K | 0.01% | 387 |
|
|
2021
Q1 | $1.06M | Buy |
27,419
+5,916
| +28% | +$224K | 0.01% | 376 |
|
|
2020
Q4 | $773K | Sell |
21,503
-919
| -4% | -$33.1K | ﹤0.01% | 389 |
|
|
2020
Q3 | $857K | Buy |
22,422
+1,068
| +5% | +$41.2K | 0.01% | 356 |
|
|
2020
Q2 | $750K | Sell |
21,354
-625
| -3% | -$22.5K | 0.01% | 368 |
|
|
2020
Q1 | $717K | Sell |
21,979
-21,087
| -49% | -$824K | 0.01% | 335 |
|
|
2019
Q4 | $1.95M | Sell |
43,066
-883
| -2% | -$36.9K | 0.01% | 184 |
|
|
2019
Q3 | $1.79M | Sell |
43,949
-566
| -1% | -$24K | 0.02% | 190 |
|
|
2019
Q2 | $1.91M | Sell |
44,515
-3,416
| -7% | -$131K | 0.02% | 164 |
|
|
2019
Q1 | $1.84M | Buy |
47,931
+379
| +0.8% | +$14.5K | 0.02% | 164 |
|
|
2018
Q4 | $1.68M | Buy |
+47,552
| New | +$1.72M | 0.02% | 153 |
|
Other funds holding BSX
Wealthfront Advisers's BSX Position: Q2 2026 in Review
Wealthfront Advisers reduced its Boston Scientific (BSX) stake by 23% in Q2 2026, selling an estimated $1.24M and leaving 76,210 shares worth $3.25M. The position accounts for 0.01% of the portfolio, ranked #529.
Wealthfront Advisers first reported a position in BSX in Q4 2018 and has held it in 31 quarters since. The position peaked at $15.9M in Q2 2025. 1,487 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Wealthfront Advisers held 76,210 shares of Boston Scientific worth $3.25M as of Q2 2026.
- Wealthfront Advisers sold 22,894 Boston Scientific shares in Q2 2026, an estimated $1.24M.
- Boston Scientific made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #529 holding.
- Wealthfront Advisers first reported a position in Boston Scientific in Q4 2018 and has held it in 31 quarters since.
- Wealthfront Advisers's Boston Scientific position peaked at $15.9M in Q2 2025.
- 1,487 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.